Marks Group Wealth Management Inc Sells 292 Shares of Amgen Inc. $AMGN

Marks Group Wealth Management Inc lessened its holdings in Amgen Inc. (NASDAQ:AMGN) by 4.8% during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 5,844 shares of the medical research company’s stock after selling 292 shares during the period. Marks Group Wealth Management Inc’s holdings in Amgen were worth $1,632,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds also recently made changes to their positions in AMGN. Brighton Jones LLC grew its stake in shares of Amgen by 23.5% in the fourth quarter. Brighton Jones LLC now owns 27,468 shares of the medical research company’s stock valued at $7,159,000 after acquiring an additional 5,226 shares in the last quarter. Sivia Capital Partners LLC boosted its holdings in Amgen by 4.5% in the 1st quarter. Sivia Capital Partners LLC now owns 1,072 shares of the medical research company’s stock valued at $334,000 after purchasing an additional 46 shares during the period. Charter Oak Capital Management LLC bought a new stake in Amgen in the 1st quarter valued at about $223,000. Patriot Financial Group Insurance Agency LLC increased its holdings in shares of Amgen by 1.4% during the first quarter. Patriot Financial Group Insurance Agency LLC now owns 4,442 shares of the medical research company’s stock worth $1,384,000 after purchasing an additional 60 shares during the period. Finally, Miracle Mile Advisors LLC raised its position in shares of Amgen by 46.1% in the first quarter. Miracle Mile Advisors LLC now owns 8,791 shares of the medical research company’s stock valued at $2,739,000 after buying an additional 2,775 shares in the last quarter. Institutional investors and hedge funds own 76.50% of the company’s stock.

Amgen Trading Down 1.3%

Shares of AMGN opened at $294.12 on Tuesday. Amgen Inc. has a twelve month low of $253.30 and a twelve month high of $335.88. The stock has a market capitalization of $158.34 billion, a P/E ratio of 24.05, a PEG ratio of 2.59 and a beta of 0.49. The company has a quick ratio of 0.98, a current ratio of 1.31 and a debt-to-equity ratio of 7.24. The firm has a fifty day simple moving average of $287.20 and a two-hundred day simple moving average of $287.83.

Amgen (NASDAQ:AMGN) last announced its earnings results on Tuesday, August 5th. The medical research company reported $6.02 EPS for the quarter, beating analysts’ consensus estimates of $5.28 by $0.74. The company had revenue of $9.18 billion during the quarter, compared to the consensus estimate of $8.86 billion. Amgen had a return on equity of 174.71% and a net margin of 18.96%.The firm’s revenue for the quarter was up 9.4% on a year-over-year basis. During the same quarter in the prior year, the company earned $4.97 earnings per share. Amgen has set its FY 2025 guidance at 20.200-21.300 EPS. On average, research analysts anticipate that Amgen Inc. will post 20.62 EPS for the current year.

Amgen Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Friday, September 12th. Investors of record on Friday, August 22nd were paid a $2.38 dividend. This represents a $9.52 dividend on an annualized basis and a yield of 3.2%. The ex-dividend date of this dividend was Friday, August 22nd. Amgen’s dividend payout ratio is presently 77.84%.

Insider Buying and Selling

In other Amgen news, SVP Nancy A. Grygiel sold 1,267 shares of Amgen stock in a transaction that occurred on Wednesday, August 20th. The stock was sold at an average price of $296.99, for a total transaction of $376,286.33. Following the sale, the senior vice president directly owned 7,209 shares of the company’s stock, valued at approximately $2,141,000.91. The trade was a 14.95% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. 0.69% of the stock is owned by company insiders.

Analyst Ratings Changes

Several analysts recently issued reports on the stock. Wall Street Zen upgraded shares of Amgen from a “hold” rating to a “buy” rating in a research report on Friday. Bank of America boosted their price objective on shares of Amgen from $261.00 to $272.00 and gave the stock an “underperform” rating in a research note on Friday, September 26th. Raymond James Financial began coverage on shares of Amgen in a research report on Wednesday, September 3rd. They issued a “market perform” rating on the stock. Cantor Fitzgerald reiterated a “neutral” rating and issued a $305.00 target price on shares of Amgen in a report on Tuesday, June 24th. Finally, Citigroup raised their price objective on shares of Amgen from $310.00 to $315.00 and gave the company a “neutral” rating in a research note on Wednesday, September 24th. Seven equities research analysts have rated the stock with a Buy rating, twelve have assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, Amgen currently has an average rating of “Hold” and an average target price of $309.42.

Amgen Company Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.